Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Nov. 21, 2014, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $96.61 to $8,962,610.00.

Highlighted Stocks Traded by Insiders:

Martin Midstream Partners (MMLP) - FREE Research Report

Bondurant Robert D, who is Executive VP and CFO at Martin Midstream Partners, bought 138 shares at $35.36 on Nov. 21, 2014. Following this transaction, the Executive VP and CFO owned 21,635 shares meaning that the stake was boosted by 0.64% with the 138-share transaction.

Booth Chris H, who is VP/General Counsel/Secretary at Martin Midstream Partners, bought 3 shares at $35.36 on Nov. 21, 2014. Following this transaction, the VP/General Counsel/Secretary owned 4,347 shares meaning that the stake was boosted by 0.06% with the 3-share transaction.

Tauscher Randall, who is Executive Vice President/COO at Martin Midstream Partners, bought 120 shares at $35.36 on Nov. 21, 2014. Following this transaction, the Executive Vice President/COO owned 13,359 shares meaning that the stake was boosted by 0.91% with the 120-share transaction.

The shares most recently traded at $34.81, down $0.55, or 1.58% since the insider transaction. Historical insider transactions for Martin Midstream Partners go as follows:

  • 4-Week # shares bought: 293
  • 4-Week # shares sold: 600
  • 12-Week # shares bought: 5,693
  • 12-Week # shares sold: 600
  • 24-Week # shares bought: 12,472
  • 24-Week # shares sold: 600

The average volume for Martin Midstream Partners has been 276,600 shares per day over the past 30 days. Martin Midstream Partners has a market cap of $1.3 billion and is part of the basic materials sector and energy industry. Shares are down 17.06% year-to-date as of the close of trading on Friday.

Martin Midstream Partners L.P. collects, transports, stores, and markets petroleum products and by-products in the United States Gulf Coast region. The stock currently has a dividend yield of 8.86%. Currently, there are 3 analysts who rate Martin Midstream Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMLP - FREE

TheStreet Quant Ratings

rates Martin Midstream Partners as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full

Martin Midstream Partners Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Control4 (CTRL) - FREE Research Report

Paisley Christopher B, who is Director at Control4, sold 1,000 shares at $15.00 on Nov. 21, 2014. Following this transaction, the Director owned 45,079 shares meaning that the stake was reduced by 2.17% with the 1,000-share transaction.

The shares most recently traded at $15.55, up $0.55, or 3.54% since the insider transaction. Historical insider transactions for Control4 go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 1,000

The average volume for Control4 has been 329,100 shares per day over the past 30 days. Control4 has a market cap of $361.6 million and is part of the technology sector and electronics industry. Shares are down 12.26% year-to-date as of the close of trading on Friday.

Control4 Corporation provides automation and control solutions for the connected home. The company has a P/E ratio of 58.2. Currently, there are 4 analysts who rate Control4 a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTRL - FREE

TheStreet Quant Ratings

rates Control4 as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full

Control4 Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Kaundinya Ganesh Venkataraman, who is Senior V.P., Research at Momenta Pharmaceuticals, sold 228 shares at $11.13 on Nov. 21, 2014. Following this transaction, the Senior V.P., Research owned 393,336 shares meaning that the stake was reduced by 0.06% with the 228-share transaction.

Shea Richard P, who is Svp, Cfo at Momenta Pharmaceuticals, sold 228 shares at $11.13 on Nov. 21, 2014. Following this transaction, the Svp, Cfo owned 177,943 shares meaning that the stake was reduced by 0.13% with the 228-share transaction.

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 228 shares at $11.13 on Nov. 21, 2014. Following this transaction, the Senior VP, Pharmaceutical Scie owned 108,915 shares meaning that the stake was reduced by 0.21% with the 228-share transaction.

Leicher Bruce, who is SVP & General Counsel at Momenta Pharmaceuticals, sold 228 shares at $11.13 on Nov. 21, 2014. Following this transaction, the SVP & General Counsel owned 127,190 shares meaning that the stake was reduced by 0.18% with the 228-share transaction.

Roach James M., who is Senior VP, Development and Chi at Momenta Pharmaceuticals, sold 250 shares at $11.13 on Nov. 21, 2014. Following this transaction, the Senior VP, Development and Chi owned 102,354 shares meaning that the stake was reduced by 0.24% with the 250-share transaction.

The shares most recently traded at $11.61, up $0.48, or 4.13% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,834
  • 12-Week # shares sold: 10,197
  • 24-Week # shares sold: 27,007

The average volume for Momenta Pharmaceuticals has been 459,900 shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $600.5 million and is part of the health care sector and drugs industry. Shares are down 34.9% year-to-date as of the close of trading on Friday.

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. Currently, there are 3 analysts who rate Momenta Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings

rates Momenta Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Momenta Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null